FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileAlterity Therapeutics Limited
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
ATH.AX
Alterity Therapeutics Limited Stock AnalysisComprehensive stock analysis for Alterity Therapeutics Limited (ATH.AX) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisATH.AX
ATH.AX
Alterity Therapeutics Limited
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
ATH.AX
  1. Home
  2. Stocks
  3. Alterity Therapeutics Limited

Alterity Therapeutics Limited

🇦🇺ATH.AX•ASX

Alterity Therapeutics Limited

🇦🇺ATH.AX•ASX

Your view on ATH.AX

Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Alterity Therapeutics Limited

Industry
Biotechnology
Sector
Healthcare
CEO
David A. Stamler
Headquarters
500 Collins Street, Melbourne, VIC, AU
Industry
Biotechnology
Sector
Healthcare
CEO
David A. Stamler
Headquarters
500 Collins Street, Melbourne, VIC, AU
Description

Based in Melbourne, Australia, Alterity Therapeutics Limited, founded in 1997, is dedicated to the discovery and advancement of treatments for neurological conditions such as Alzheimer's, Huntington's, and Parkinson's diseases, among others.

The company's primary drug candidate, ATH434, has successfully navigated Phase I clinical trials for Parkinson's disease. Additionally, it is progressing PBT2, an investigational compound for Alzheimer's disease that has completed Phase 2a clinical trials.

The firm, previously known as Prana Biotechnology Limited, adopted its current name, Alterity Therapeutics Limited, in April 2019.

Financial Data

Stock Data

Price chart, volume, and trading data.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for Alterity Therapeutics Limited. Starting points for Alterity Therapeutics Limited: EPS -AUD 0.11, beta -0.04 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

About this section

Dividend history, yield and payout sustainability for Alterity Therapeutics Limited. Alterity Therapeutics Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for Alterity Therapeutics Limited. Trailing twelve-month EPS for Alterity Therapeutics Limited stands at -AUD 0.11. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Wall Street Analyst Estimates

Analysts' price targets, ratings, and revenue and EPS estimates.

Wall Street analysts· not FRC research
Nov 20, 2026

Buy

Analyst ratings

2 ratings
  • Strong Buy0
  • Buy2
  • Hold0
  • Sell0
  • Strong Sell0
More →

Earnings per share estimates

Per shareThis quarterDec 2026Next quarterJun 2027This yearYear to Jun 2027Next yearYear to Jun 2028
Average estimate−AUD 0.00−AUD 0.01−AUD 0.01−AUD 0.02
Lowest estimate−AUD 0.00−AUD 0.01−AUD 0.01−AUD 0.02
Highest estimate−AUD 0.00−AUD 0.01−AUD 0.01−AUD 0.02
Number of analysts1145
A year ago−AUD 0.10−AUD 0.04−AUD 0.111—
Growth vs a year ago+96.9%+80.3%——

1The year-ago figure includes one-time items, so growth is not shown.

Revenue estimates

TotalThis quarterDec 2026Next quarterJun 2027This yearYear to Jun 2027Next yearYear to Jun 2028
Average estimateAUD 1.13MAUD 1.43MAUD 2.34MAUD 4.87M
Lowest estimateAUD 1.13MAUD 1.43MAUD 2.34MAUD 4.87M
Highest estimateAUD 1.13MAUD 1.43MAUD 2.34MAUD 4.87M
Number of analysts1166
A year agoAUD 1.61MAUD 3.83MAUD 0.00—
Growth vs a year ago−29.4%−62.6%——
Recent rating and target changes (2)

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for Alterity Therapeutics Limited. Alterity Therapeutics Limited has reported as a listed company since 2000. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold ATH.AX19 companies
Compare ATH.AX with its peers, side by sidePremiumRatios, margins, valuation and leverage of the peers below — one table, one glance.Open Comparable Analysis
Peer companies
TickerTypeCompanySectorIndustry
ACW.AXActinogen Medical LimitedHealthcareBiotechnology—
AGN.AXArgenica Therapeutics LtdHealthcareBiotechnology—
ALA.AXArovella Therapeutics LimitedHealthcareBiotechnology—
IXC.AXInvex Therapeutics LtdHealthcareBiotechnology—
NEU.AXNeuren Pharmaceuticals LimitedHealthcareBiotechnology—
NSB.AXNeuroScientific Biopharmaceuticals LimitedHealthcareBiotechnology—
NUZ.AXNeurizon Therapeutics LimitedHealthcareBiotechnology—
More Biotechnology companies
TickerTypeCompanySectorExchangeMkt cap
OZYMFStrategic Partners A/SHealthcareOTC$3.7M
PAB.AXPatrys LimitedHealthcareASX—
PALIPalisade Bio, Inc.HealthcareNASDAQ$168.9M
PANCPanacos Pharmaceuticals, Inc.HealthcareOTC$5,367
PAR.AXParadigm Biopharmaceuticals LimitedHealthcareASX—
PARDPoniard Pharmaceuticals, Inc.HealthcareOTC$150
PASGPassage Bio, Inc.HealthcareNASDAQ$12.9M
PBIGFParadigm Biopharmaceuticals LimitedHealthcareOTC$87.9M
PBLAPanbela Therapeutics, Inc.HealthcareOTC$53,889
PBLSParabilis Medicines, Inc.HealthcareNASDAQ$3.5B
PBMPsyence Biomedical Ltd.HealthcareNASDAQ$47,738
PBMWWPsyence Biomedical Ltd. WarrantHealthcareNASDAQ$869
Open Comparable Analysis
Ownership & News

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for Alterity Therapeutics Limited. Coverage tracks Alterity Therapeutics Limited within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of Alterity Therapeutics Limited.

ATH.AX AnalysisWeak
Past
1
Growth
1
Health
5
Profit
1
Value
1